Key Points
- Edwin Reisz sold 60,769 shares on Feb. 19 at an average price of $7.21 for about $438,144, leaving him with 1,447,057 shares (a 4.03% reduction in his position).
- There was large, concentrated insider selling across Feb. 17–19 — including CEO Jeff Shaner (~461,900 shares) and other executives — a move market commentators tied to a recent ~5.7% pullback and viewed as a negative catalyst.
- Despite the insider sales, institutional ownership remains high (~87.96%), with major funds like Vanguard increasing their stake (Vanguard up 38% to ~5.58 million shares), signaling continued institutional interest.
Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH - Get Free Report) CAO Deborah Stewart sold 7,738 shares of Aveanna Healthcare stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $7.65, for a total transaction of $59,195.70. Following the completion of the transaction, the chief accounting officer owned 323,884 shares of the company's stock, valued at $2,477,712.60. This represents a 2.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Deborah Stewart also recently made the following trade(s):
- On Thursday, February 19th, Deborah Stewart sold 11,181 shares of Aveanna Healthcare stock. The shares were sold at an average price of $7.21, for a total transaction of $80,615.01.
- On Wednesday, February 18th, Deborah Stewart sold 10,896 shares of Aveanna Healthcare stock. The shares were sold at an average price of $7.38, for a total transaction of $80,412.48.
- On Friday, January 2nd, Deborah Stewart sold 11,962 shares of Aveanna Healthcare stock. The stock was sold at an average price of $7.85, for a total transaction of $93,901.70.
- On Wednesday, December 31st, Deborah Stewart sold 11,275 shares of Aveanna Healthcare stock. The shares were sold at an average price of $8.18, for a total value of $92,229.50.
- On Tuesday, December 30th, Deborah Stewart sold 11,379 shares of Aveanna Healthcare stock. The shares were sold at an average price of $8.36, for a total value of $95,128.44.
Aveanna Healthcare Stock Down 1.8%
NASDAQ AVAH traded down $0.13 during trading on Friday, reaching $7.29. 224,424 shares of the company's stock were exchanged, compared to its average volume of 1,230,737. The company has a 50 day moving average price of $8.48 and a two-hundred day moving average price of $8.44. The stock has a market cap of $1.52 billion, a P/E ratio of 20.26 and a beta of 2.06. Aveanna Healthcare Holdings Inc. has a 1 year low of $3.67 and a 1 year high of $10.32. The company has a debt-to-equity ratio of 140.39, a quick ratio of 1.23 and a current ratio of 1.23.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. Invesco Ltd. boosted its stake in shares of Aveanna Healthcare by 1,001.5% during the fourth quarter. Invesco Ltd. now owns 360,464 shares of the company's stock worth $2,945,000 after buying an additional 327,738 shares during the period. Mackenzie Financial Corp raised its stake in Aveanna Healthcare by 12.7% during the 4th quarter. Mackenzie Financial Corp now owns 216,200 shares of the company's stock valued at $1,810,000 after acquiring an additional 24,447 shares during the last quarter. Zimmer Partners LP acquired a new stake in Aveanna Healthcare during the 4th quarter worth approximately $6,189,000. Voloridge Investment Management LLC purchased a new position in shares of Aveanna Healthcare in the 4th quarter valued at approximately $1,915,000. Finally, Millennium Management LLC increased its holdings in shares of Aveanna Healthcare by 1,007.1% in the fourth quarter. Millennium Management LLC now owns 1,114,717 shares of the company's stock valued at $9,107,000 after purchasing an additional 1,014,030 shares during the period. 87.96% of the stock is currently owned by institutional investors and hedge funds.
Key Aveanna Healthcare News
Here are the key news stories impacting Aveanna Healthcare this week:
- Positive Sentiment: Insiders still retain meaningful stakes — despite the sales, CEO Jeff Shaner, CFO Matthew Buckhalter and other insiders continue to hold multi‑million‑dollar positions, which may signal ongoing alignment with shareholders. SEC Filing
- Neutral Sentiment: Reported short interest data shows zero shares (likely a data/reporting anomaly), so there’s no clear short‑selling pressure indicated by that statistic. Short Interest
- Neutral Sentiment: Today’s trading volume was well below the recent average, which can amplify price moves when large block trades or news hit the tape. (Context from recent price/volume data.)
- Negative Sentiment: Large, concentrated insider selling across Feb. 17–19: CEO Jeff Shaner sold roughly 461,900 shares across the three days (totaling about $3.4M), other executives including an additional director and senior officers sold substantial blocks, and cumulative insider disposals during the period totalled in the high hundreds of thousands of shares — a clear negative catalyst that likely pushed the stock down. See CEO filings. CEO Sales SEC Filing
- Negative Sentiment: Multiple additional executive/director sales (CFO, CAO, and other insiders sold across the same dates), including material dispositions by Edwin C. Reisz and Patrick A. Cunningham, reinforcing a market interpretation that insiders are taking profits or reducing exposure at current levels. Example filings here. Other Insider Filings
- Negative Sentiment: Coverage/analysis noting the drop: independent commentary flagged the same insider selling as the primary reason for a recent ~5.7% pullback, reinforcing market attention on the sales. AAII Article
Wall Street Analyst Weigh In
A number of analysts have weighed in on the stock. Weiss Ratings reissued a "hold (c+)" rating on shares of Aveanna Healthcare in a report on Monday, December 29th. Jefferies Financial Group increased their target price on shares of Aveanna Healthcare from $11.00 to $12.50 and gave the company a "buy" rating in a research report on Tuesday, October 28th. Truist Financial boosted their price target on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the company a "hold" rating in a research report on Friday, November 7th. Royal Bank Of Canada raised their price objective on Aveanna Healthcare from $10.00 to $11.00 and gave the stock a "sector perform" rating in a report on Thursday, January 15th. Finally, Raymond James Financial reissued an "outperform" rating and issued a $13.00 target price on shares of Aveanna Healthcare in a report on Friday, December 5th. Five investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, Aveanna Healthcare has an average rating of "Hold" and an average target price of $11.06.
Get Our Latest Research Report on Aveanna Healthcare
About Aveanna Healthcare
(
Get Free Report)
Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna's offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.
In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
